New Protein Test Predicts Colorectal Cancer Treatment

Imagine walking into your local hospital for a routine cancer test and walking out with a personalized roadmap to the treatment most likely to cure you. That future just got closer thanks to researchers in Spain who've identified a protein marker that predicts which colorectal cancer patients will respond to specific treatments.

The breakthrough centers on a protein called CTHRC1, found in certain cells surrounding tumors. A team from Barcelona's Hospital del Mar Research Institute studied nearly 3,000 patient samples across 17 different groups and discovered something remarkable: measuring this single protein can predict both how well patients will respond to treatment and their overall prognosis.

Dr. Alexandre Calon, who led the research published in the journal Gut, points out the marker's consistency. "The validated marker maintains strong predictive and prognostic performance across patient cohorts," he explains, meaning it works reliably for diverse groups of people.

The discovery addresses one of cancer treatment's biggest frustrations. Currently, only about 5% of colorectal cancer patients qualify for immunotherapy, the revolutionary treatment that harnesses the body's immune system to fight cancer. Even among those who qualify, it doesn't always work.

This new test changes the equation. By measuring CTHRC1 levels, doctors can now identify additional patients who might benefit from immunotherapy, potentially expanding treatment options for thousands more people each year.

Dr. Clara Montagut, Head of Medical Oncology at Hospital del Mar, emphasizes the practical impact. "This biomarker improves the selection of patients who could potentially benefit from immunotherapy," she notes, adding it "could help guide therapeutic strategies for patients with colon and rectal cancer."

The Bright Side

What makes this discovery especially promising is how accessible it is. The test uses immunohistochemistry, a standard procedure already available in virtually every hospital pathology lab. No expensive new equipment needed, no specialized training required.

Dr. Mar Iglesias, who headed the pathology work, celebrates this simplicity. "The results position CTHRC1 as a useful marker with the potential to be integrated into routine clinical practice in our services and hospitals," she explains.

The implications reach beyond colorectal cancer too. Early evidence suggests the same marker could help guide treatment decisions for breast and lung cancer patients, multiplying the potential impact.

For the 1.9 million people diagnosed with colorectal cancer globally each year, this represents genuine hope: better treatment matching, fewer ineffective therapies, and more lives saved through precision medicine that's actually practical to deliver.